Basics CorMedix Inc. Cormedix Inc is a commercial-stage biopharmaceutical company. It focuses on development and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. IPO Date: May 13, 2010 Sector: Healthcare Industry: Biotech Market Cap: $925.65M Activated in VL: True Average Daily Range Avg Daily Range: $0.13 | 4.12% Avg Daily Range (30 D): $0.35 | 2.82% Avg Daily Range (90 D): $0.32 | 2.62% Institutional Daily Volume Avg Daily Volume: .56M Avg Daily Volume (30 D): 3.85M Avg Daily Volume (90 D): 2.53M Trade Size Avg Trade Size (Sh.): 214 Avg Trade Size (Sh.) (30 D): 136 Avg Trade Size (Sh.) (90 D): 120 Institutional Trades Total Inst.Trades: 614 Avg Inst. Trade: $1.47M Avg Inst. Trade (30 D): $1.48M Avg Inst. Trade (90 D): $1.46M Avg Inst. Trade Volume: .14M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $1.78M Avg Closing Trade (30 D): $2.18M Avg Closing Trade (90 D): $2.05M Avg Closing Volume: 186.9K     News Sep 2, 2025 @ 11:30 AM CorMedix Completes Acquisition of Melinta Therapeu... Source: Globe Newswire Dec 10, 2024 @ 7:45 AM Closed System Transfer Device Market Size Poised t... Source: Polaris Market Research Sep 9, 2024 @ 8:06 PM Here's Why CorMedix Is a Great 'Buy the Bottom' St... Source: Zacks Sep 9, 2024 @ 2:52 PM CorMedix Inc. Announces New Commercial Agreement Source: N/A Jun 6, 2024 @ 12:30 PM CorMedix Inc. Announces CMS Grants Pass-Through St... Source: CorMedix, Inc. Financials   TTM Q2 2025 Q1 2025 Basic EPS $.79 $.29 $.32 Diluted EPS $.77 $.28 $.3 Revenue $ 121.48M $ 39.74M $ 39.08M Gross Profit $ 116.16M $ 37.87M $ 37.48M Net Income / Loss $ 51.16M $ 19.83M $ 20.64M Operating Income / Loss $ 49.32M $ 19.54M $ 20.13M Cost of Revenue $ 5.32M $ 1.86M $ 1.6M Net Cash Flow $ 130.77M $ 93.02M $ 25.63M PE Ratio 16.21     Splits Mar 26, 2019:   1:5